New hope for older aplastic anemia patients: drug combo may prevent dangerous transplant side effect

NCT ID NCT06752694

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tests whether adding the drug ruxolitinib to standard care can prevent graft-versus-host disease (GVHD) in older adults with aplastic anemia who receive a stem cell transplant. GVHD is a common and serious complication where donor cells attack the patient's body. The trial enrolls 20 participants aged 40 and older (or younger adults with high health risks) and aims to reduce GVHD without using a harsh immune-suppressing drug called ATG.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

APLASTIC ANEMIA